ARS Pharmaceuticals, Inc. (SPRY)
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $84.3M
- Net income
- -$171.3M
- Total assets
- $327.7M
- Market cap
- $850.0M
- Operating margin
- -212.9%
- Net margin
- -203.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $84.3M
- Operating expenses
- $263.7M
- Operating income
- -$179.4M
- Income tax
- -$80.0K
- Net income
- -$171.3M
- EPS (basic)
- $-1.74
- EPS (diluted)
- $-1.74
Balance sheet
- Total assets
- $327.7M
- Current assets
- $284.9M
- Total liabilities
- $213.4M
- Current liabilities
- $39.1M
- Shareholders’ equity
- $114.3M
Cash flow
- Operating cash flow
- -$170.9M
- Investing cash flow
- $56.8M
- Financing cash flow
- $104.6M
- Net cash flow
- -$9.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $850.0M
- EPS (diluted)
- $-1.74
- Shares outstanding
- 143.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 9, 2022
ARS Pharmaceuticals, Inc. (SPRY) Stock Price
- Reported a net loss of $171.3M in FY2025.
- Revenue grew 6304% from FY2022 to FY2025.
- Trading 68% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ARS Pharmaceuticals, Inc..
Write a review
News about ARS Pharmaceuticals, Inc.
News & sentiment via Polygon.io
ARS Pharmaceuticals, Inc.: frequently asked questions
Is ARS Pharmaceuticals, Inc. an American company?
ARS Pharmaceuticals, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is ARS Pharmaceuticals, Inc. headquartered?
ARS Pharmaceuticals, Inc. is headquartered in San Diego, California, United States.
Is ARS Pharmaceuticals, Inc. publicly traded?
Yes — ARS Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol SPRY on the NASDAQ.
What does ARS Pharmaceuticals, Inc. do?
ARS Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
